Analyst Reco. Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Real-time Estimate Cboe BZX Other stock markets 14:50:30 29/04/2024 BST			5-day change	1st Jan Change
8.775 ^USD	+0.75%		+4.24%	+9.83%

04-25	Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	MT
04-25	Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Trims Price Target on Bausch Health to $11 From $12, Keeps Sector Perform Rating	04-23	MT
Bausch Health's Issuer Credit Rating Upgraded by S&P	04-19	MT
Trump eyes $43 million haul from biggest fundraiser yet	04-06	RE
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating	04-05	MT
RBC Lifts Price Target on Bausch Health to $9 From $8, Keeps Sector Perform Rating	02-23	MT
North American Morning Briefing : Mood Lifted on Hopes Rate-Hike Cycle Has Peaked	11-02	DJ
RBC Cuts Price Target on Bausch Health to $8 From $9 Ahead of Q3 Report, Keeps Sector Perform Rating	23/10/23	MT
Fitch Affirms Bausch Health, Bausch Health America's Ratings; Bausch + Lomb's Rating Maintained	04/10/23	MT
Jefferies Upgrades Bausch Health to Buy From Hold, Adjusts Price Target to $16 From $9	20/09/23	MT
Moody's Rates Bausch + Lomb's New Secured Debt Instruments	12/09/23	MT
RBC Boosts Price Target on Bausch Health to $9 From $8 Ahead of Q2 Report, Maintains Sector Perform Rating	24/07/23	MT
TD Cowen Downgrades Bausch Health to Market Perform From Outperform, Adjusts Price Target to $12 From $35	16/06/23	MT
Jefferies Adjusts Price Target on Bausch Health to $9.50 From $7, Maintains Hold Rating	22/05/23	MT
RBC Cuts Price Target on Bausch Health to $8 From $9, Notes Concerns for Ability to Distribute Bausch + Lomb Shares, Keeps Sector Perform Rating	05/05/23	MT
Factbox-US government to impose inflation penalties on 27 drugs	15/03/23	RE
Bausch Health Price Target Raised to US$10 (From US$8), Market Perform Rating Maintained After "Solid Q4" and 2023 Guide	24/02/23	MT
RBC Lifts Price Target on Bausch Health to $9 From $8, Maintains Sector Perform Rating	24/02/23	MT
Fitch Lowers Bausch Health to RD; Upgrades to CCC Post Distressed Exchange; Also Downgrades Bausch + Lomb	07/10/22	MT
Fitch Downgrades Bausch Health to 'RD'; Upgrades to 'CCC' Post Distressed Exchange	07/10/22	AQ
Fitch Downgrades Bausch + Lomb's IDR to 'B-'; Evolving Rating Watch Pre and Post Downgrade	07/10/22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Analyst Reco.

Filters